Short answer
NOVAVAX INC (NVAX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $57M (down 76.3% year over year) with net income of −$53M.
Q2 2026 key financials · XBRL
- Revenue
- $57M
- −76.3% YoY · −59.4% QoQ
- Net income
- −$53M
- −150.1% YoY · −462.5% QoQ
- Operating margin
- -96.8%
- EPS (diluted)
- −$0.32
- −151.6% YoY · −433.3% QoQ
Source: XBRL data from the NOVAVAX INC (NVAX) Q2 2026 10-Q on SEC EDGAR. USD.
NOVAVAX INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue, profitability, segments, cash flow, and capital deployment figures absent from provided excerpt
- Outlook: Sanofi CIC Phase 3 timing under regulatory discussion, potentially triggering $125 million milestone
- Sanofi manufacturing transfer expected mid-2027, potentially triggering $75 million milestone
- Headwinds: COVID-19 demand, regulatory uncertainty, manufacturing delays, funding needs, and partnership execution risks
Risk Factors
- No risk-factors section provided; supplied text covers Items 5–6 and signatures only
- Stock-plan dilution risk: 9,400,000 additional shares authorized under the Amended 2015 Stock Plan
- Employee-equity dilution risk: ESPP share pool increased by 1,000,000 shares
- Governance-compliance disclosure: stockholders approved both plan amendments on June 18, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NOVAVAX INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.